← Back to Search

ACTH Receptor Antagonist

CRN04894 for Cushing's Syndrome

Phase 1 & 2
Recruiting
Research Sponsored by Crinetics Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will study a new drug to treat Cushing's Syndrome, a hormone disorder, to see if it is safe and effective.

Who is the study for?
This trial is for adults aged 18-75 with active ACTH-dependent Cushing's syndrome, vaccinated against COVID-19. Participants on short-term steroid inhibitors can join after a washout period. It excludes pregnant or lactating women, those with certain pituitary issues, recent unsuccessful surgery for Cushing's, and anyone with known cancer or extremely high urine cortisol levels.
What is being tested?
The study tests CRN04894 in people with Cushing's syndrome to see how safe it is and how the body processes it. This drug blocks the action of ACTH which causes overproduction of cortisol. The trial involves increasing doses to find out what amount works best without being harmful.
What are the potential side effects?
Potential side effects aren't specified but may include reactions related to lowering cortisol production too much such as fatigue, nausea, dizziness or potentially affecting other hormones regulated by ACTH.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Multiple Ascending DosesExperimental Treatment1 Intervention
Sequential, open-label, 10-day fixed-dose cohorts.

Find a Location

Who is running the clinical trial?

Crinetics Pharmaceuticals Inc.Lead Sponsor
11 Previous Clinical Trials
593 Total Patients Enrolled

Media Library

CRN04894 (ACTH Receptor Antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT05804669 — Phase 1 & 2
Corticotropin Syndrome Research Study Groups: Multiple Ascending Doses
Corticotropin Syndrome Clinical Trial 2023: CRN04894 Highlights & Side Effects. Trial Name: NCT05804669 — Phase 1 & 2
CRN04894 (ACTH Receptor Antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05804669 — Phase 1 & 2
~11 spots leftby Oct 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top